About GRAIL, Inc.
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Joshua Ofman is CEO.
2BB score and signals
GRAIL, Inc.’s current 2BB score is 48 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 69 | High |
| Momentum | 57 | Stable |
| Financial strength | 39 | Weak |
| Quality | 98 | Very Strong |
| Risk | 44 | Moderate |
Company facts
| Headquarters | Menlo Park, California, United States |
| Founded | 2015 |
| Employees | 910 |
| 52-week range | $41.50 – $166.48 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-17 | — | -2.6429 | — | $52.18M |
| 2026-11-10 | — | -2.652 | — | $45.18M |
| 2026-08-05 | — | -2.7053 | — | $43.62M |
| 2026-05-05 | -2.29 | -2.8181 | $40.78M | $39.95M |
Related companies
